601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF
monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO